Literature DB >> 25433789

[Quality control of oral anticoagulant therapy in Primary Care in Madrid City, Spain: CHRONOS-TAO study].

Rafael Alonso Roca1, Carmen Arlene Figueroa Guerrero2, Victoria Mainar de Paz3, M Paz Arribas García4, Luis Sánchez Perruca5, Ricardo Rodríguez Barrientos6, Mariano Casado López5, Ana M Pedraza Flechas7.   

Abstract

OBJECTIVES: To determine quality control of patients with oral anticoagulant treatment recruited in Primary Care (PC) using the Rosendaal method to estimate time in therapeutic range (TTR) and comparing it with fraction of international normalized ratio (INR) in range and cross-sectional analysis (last INR registred). MATERIAL AND
METHOD: A retrospective observational study based on electronic medical record in routine clinical practice.
SETTING: PC centers (262) in Madrid. We included all patients with acenocumarol treatment, with an INR therapeutic range established between 2 and 3. We excluded patients with valvular pathology and disrupted clinical follow up in PC (<3 INR determinations in the studied period, a period of>90 days or ≥ 3 periods of>60 days between 2 determinations). The final population was 49,312 patients. The variables considered were all INR values and their respective dates. TTR was calculated by the 3 methods above mentioned. We considered "therapeutic range" INR between 2-3 and "adjusted range" INR between 1.8-3.2. Optimal control for each patient was considered TTR>60%.
RESULTS: By using Rosendaal method, TTR was 66.8% (81.7% adjusted), with a percentage of total INR in range was 58.8% (66.5% adjusted), and, with the cross-sectional analysis, it was 70.5% (76.8% adjusted). Mean TTR was 65% (standard deviation 20.3), and the percentage of patients with TTR>60% was 63.3% (88.1% adjusted).
CONCLUSION: The quality control of patients with oral anticoagulants in PC in Madrid is acceptable, similar or higher to other studies and pivotal trials of new anticoagulants. Compared to the Rosendaal method, total fraction of INR underestimates quality control, and cross-sectional analysis slightly overestimates it.
Copyright © 2014 Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Anticoagulantes; Anticoagulants; Atención Primaria; Grado de control; International normalized ratio; Primary Care; Quality control; Razón normalizada internacional

Mesh:

Substances:

Year:  2014        PMID: 25433789     DOI: 10.1016/j.medcli.2014.09.023

Source DB:  PubMed          Journal:  Med Clin (Barc)        ISSN: 0025-7753            Impact factor:   1.725


  6 in total

1.  Quality of Chronic Anticoagulation Control in Patients with Intracranial Haemorrhage due to Vitamin K Antagonists.

Authors:  Carlos Estevez-Fraga; Maria Molina-Sanchez; Rodrigo Alvarez-Velasco; Pablo Agüero-Rabes; Leticia Crespo-Araico; Elena Viedma-Guiard; Antonio Cruz-Culebras; Consuelo Matute; Rocio Vera; Alicia De Felipe-Mimbrera; Jaime Masjuan Vallejo
Journal:  Stroke Res Treat       Date:  2018-08-02

2.  Quality of INR control and switching to non-Vitamin K oral anticoagulants between women and men with atrial fibrillation treated with Vitamin K Antagonists in Spain. A population-based, real-world study.

Authors:  Aníbal García-Sempere; Isabel Hurtado; Daniel Bejarano-Quisoboni; Clara Rodríguez-Bernal; Yared Santa-Ana; Salvador Peiró; Gabriel Sanfélix-Gimeno
Journal:  PLoS One       Date:  2019-02-12       Impact factor: 3.240

3.  [Prevalence of oral anticoagulation and quality of its management in primary healthcare: A study by the Health Sentinel Network of the Region of Valencia (Spain)].

Authors:  Ana Boned-Ombuena; Jordi Pérez-Panadés; Aurora López-Maside; Maite Miralles-Espí; Sandra Guardiola Vilarroig; Desamparados Adam Ruiz; Oscar Zurriaga
Journal:  Aten Primaria       Date:  2017-04-10       Impact factor: 1.137

4.  Cost of incorrect application of antithrombotic prophylaxis prior to invasive procedures.

Authors:  Ma Victoria Cuevas; Ignacio Martínez-Sancho; Jana Arribas; Covadonga García-Díaz; Beatriz Cuevas
Journal:  BMC Health Serv Res       Date:  2019-11-06       Impact factor: 2.655

5.  [Multiple morbidity patterns, level of control and haemorrhagic risk in patients with vitamin K antagonists].

Authors:  David Pérez-Manchón; Gema María Álvarez-García; Montserrat Ruíz-López; Jesús Guodemar-Pérez; Juan Pablo Hervás-Pérez
Journal:  Aten Primaria       Date:  2017-11-11       Impact factor: 1.137

Review 6.  Magnitudes of Risk Factors of Venous Thromboembolism and Quality of Anticoagulant Therapy in Ethiopia: A Systematic Review.

Authors:  Bekalu Kebede; Tirsit Ketsela
Journal:  Vasc Health Risk Manag       Date:  2022-04-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.